Enhancement patterns of small hepatocellular carcinoma (≤ 30 mm) on contrast-enhanced ultrasound: correlation with clinicopathologic characteristics
Publication date: Available online 8 October 2020Source: European Journal of RadiologyAuthor(s): Pei Li Fan, Hong Ding, Feng Mao, Ling Li Chen, Yi Dong, Wen Ping Wang
Authors: Jeffrey GP PMID: 33030253 [PubMed - as supplied by publisher]
This article reviews clinical burden of NAFLD, and the role of noninvasive imaging techniques for quantification of liver fat.
CONCLUSIONS: The intraprocedurally application of EOB-MRI/US FI to determine ablation scope according to HBP findings is feasible and beneficial for prognosis of RFA. PMID: 32996799 [PubMed - in process]
Condition: Hepatocellular Carcinoma Intervention: Drug: Lumason Sponsors: Milton S. Hershey Medical Center; Penn State Health Liver Center Not yet recruiting
Despite advances in interventional procedures and chemotherapeutic drug development, hepatocellular carcinoma (HCC) is still the fourth leading cause of cancer-related deaths worldwide with a
Publication date: Available online 28 September 2020Source: Hepatobiliary &Pancreatic Diseases InternationalAuthor(s): Qi-Yu Zhao, Li-Ting Xie, Shuo-Chun Chen, Xiao Xu, Tian-An Jiang, Shu-Sen Zheng
Conclusions: Percutaneous US-guided MWA is safe and effective in terms of local control and survival of adrenal metastasis.
Conclusions: EUS-FNB is a sensitive and safe diagnostic modality for cirrhotic patients with suspected HCC located in the left lobe, especially those for whom percutaneous biopsy is contraindicated.